Association between the characteristics of metabolic syndrome and Alzheimer's disease

Hui Ting Yang, Yi Jing Sheen, Chuen Der Kao, Chin An Chang, Ya Chun Hu, Jiann Liang Lin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Various epidemiological studies have shown that type 2 diabetes and metabolic syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to assess the impact of metabolic syndrome characteristics on the progression of AD. Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY, hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD), and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were sacrificed and samples of the blood, liver, and brain were collected for further biological analysis. During the 15-week period of induction, the STZ and DM groups (animals injected with low-dose STZ) had significantly higher fasting glucose levels; the HFD group had elevated insulin levels, but normal blood glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic levels of triglycerides and cholesterol. Additionally, correlations between HFD and elevated brain amyloid-beta 42 (Aβ-42), hyperglycemia and down-regulation of brain insulin receptor, and serum Aβ-42 and hepatic triglyceride concentrations (r2 = 0.41, p < 0.05) were observed. Serum C-reactive protein and malondialdehyde did not appear to have a significant influence on the association with biomarkers of AD. Thus, our study demonstrated that rats with characteristics of metabolic syndrome had a large number of biomarkers predicting AD; however, no relationship between traditional inflammatory and oxidative markers and AD was found. Further studies are necessary to prove that these findings in rats are relevant to AD processes in humans.

Original languageEnglish
Pages (from-to)597-604
Number of pages8
JournalMetabolic Brain Disease
Volume28
Issue number4
DOIs
Publication statusPublished - Dec 1 2013
Externally publishedYes

Fingerprint

Metabolic Diseases
Medical problems
High Fat Diet
Alzheimer Disease
Experimental Diabetes Mellitus
Nutrition
Streptozocin
Fats
Diabetes Mellitus
Rats
Brain
Liver
Triglycerides
Biomarkers
Animals
Insulin Receptor
Hypercholesterolemia
Malondialdehyde
Amyloid
Hyperglycemia

Keywords

  • Alzheimer's disease (AD)
  • Amyloid beta-42 (Aβ-42)
  • Amyloid precursor protein (APP)
  • Metabolic syndrome

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Association between the characteristics of metabolic syndrome and Alzheimer's disease. / Yang, Hui Ting; Sheen, Yi Jing; Kao, Chuen Der; Chang, Chin An; Hu, Ya Chun; Lin, Jiann Liang.

In: Metabolic Brain Disease, Vol. 28, No. 4, 01.12.2013, p. 597-604.

Research output: Contribution to journalArticle

Yang, Hui Ting ; Sheen, Yi Jing ; Kao, Chuen Der ; Chang, Chin An ; Hu, Ya Chun ; Lin, Jiann Liang. / Association between the characteristics of metabolic syndrome and Alzheimer's disease. In: Metabolic Brain Disease. 2013 ; Vol. 28, No. 4. pp. 597-604.
@article{3fc943a658af442884a7373697970fc7,
title = "Association between the characteristics of metabolic syndrome and Alzheimer's disease",
abstract = "Various epidemiological studies have shown that type 2 diabetes and metabolic syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to assess the impact of metabolic syndrome characteristics on the progression of AD. Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY, hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD), and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were sacrificed and samples of the blood, liver, and brain were collected for further biological analysis. During the 15-week period of induction, the STZ and DM groups (animals injected with low-dose STZ) had significantly higher fasting glucose levels; the HFD group had elevated insulin levels, but normal blood glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic levels of triglycerides and cholesterol. Additionally, correlations between HFD and elevated brain amyloid-beta 42 (Aβ-42), hyperglycemia and down-regulation of brain insulin receptor, and serum Aβ-42 and hepatic triglyceride concentrations (r2 = 0.41, p < 0.05) were observed. Serum C-reactive protein and malondialdehyde did not appear to have a significant influence on the association with biomarkers of AD. Thus, our study demonstrated that rats with characteristics of metabolic syndrome had a large number of biomarkers predicting AD; however, no relationship between traditional inflammatory and oxidative markers and AD was found. Further studies are necessary to prove that these findings in rats are relevant to AD processes in humans.",
keywords = "Alzheimer's disease (AD), Amyloid beta-42 (Aβ-42), Amyloid precursor protein (APP), Metabolic syndrome",
author = "Yang, {Hui Ting} and Sheen, {Yi Jing} and Kao, {Chuen Der} and Chang, {Chin An} and Hu, {Ya Chun} and Lin, {Jiann Liang}",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s11011-013-9406-2",
language = "English",
volume = "28",
pages = "597--604",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Association between the characteristics of metabolic syndrome and Alzheimer's disease

AU - Yang, Hui Ting

AU - Sheen, Yi Jing

AU - Kao, Chuen Der

AU - Chang, Chin An

AU - Hu, Ya Chun

AU - Lin, Jiann Liang

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Various epidemiological studies have shown that type 2 diabetes and metabolic syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to assess the impact of metabolic syndrome characteristics on the progression of AD. Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY, hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD), and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were sacrificed and samples of the blood, liver, and brain were collected for further biological analysis. During the 15-week period of induction, the STZ and DM groups (animals injected with low-dose STZ) had significantly higher fasting glucose levels; the HFD group had elevated insulin levels, but normal blood glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic levels of triglycerides and cholesterol. Additionally, correlations between HFD and elevated brain amyloid-beta 42 (Aβ-42), hyperglycemia and down-regulation of brain insulin receptor, and serum Aβ-42 and hepatic triglyceride concentrations (r2 = 0.41, p < 0.05) were observed. Serum C-reactive protein and malondialdehyde did not appear to have a significant influence on the association with biomarkers of AD. Thus, our study demonstrated that rats with characteristics of metabolic syndrome had a large number of biomarkers predicting AD; however, no relationship between traditional inflammatory and oxidative markers and AD was found. Further studies are necessary to prove that these findings in rats are relevant to AD processes in humans.

AB - Various epidemiological studies have shown that type 2 diabetes and metabolic syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to assess the impact of metabolic syndrome characteristics on the progression of AD. Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY, hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD), and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were sacrificed and samples of the blood, liver, and brain were collected for further biological analysis. During the 15-week period of induction, the STZ and DM groups (animals injected with low-dose STZ) had significantly higher fasting glucose levels; the HFD group had elevated insulin levels, but normal blood glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic levels of triglycerides and cholesterol. Additionally, correlations between HFD and elevated brain amyloid-beta 42 (Aβ-42), hyperglycemia and down-regulation of brain insulin receptor, and serum Aβ-42 and hepatic triglyceride concentrations (r2 = 0.41, p < 0.05) were observed. Serum C-reactive protein and malondialdehyde did not appear to have a significant influence on the association with biomarkers of AD. Thus, our study demonstrated that rats with characteristics of metabolic syndrome had a large number of biomarkers predicting AD; however, no relationship between traditional inflammatory and oxidative markers and AD was found. Further studies are necessary to prove that these findings in rats are relevant to AD processes in humans.

KW - Alzheimer's disease (AD)

KW - Amyloid beta-42 (Aβ-42)

KW - Amyloid precursor protein (APP)

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84887233266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887233266&partnerID=8YFLogxK

U2 - 10.1007/s11011-013-9406-2

DO - 10.1007/s11011-013-9406-2

M3 - Article

VL - 28

SP - 597

EP - 604

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

IS - 4

ER -